Blogs - iGeneTech Bioscience Co., Ltd.

05

03, 2026

How is the Sensitivity of AML MRD Monitoring Calculated?

Relapse remains the core challenge in the treatment of acute myeloid leukemia (AML). Measurable residual disease (MRD), the most robust independent prognostic marker for assessing remission depth and ...



12

02, 2026

Based on SNP NGS Chimerism Detection: Sensitive Detection of 0.01% Chimerism Rate

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal curative option for approximately 50% of adult patients with acute leukemia, as well as those with intermediate/high-risk ...



03

02, 2026

Multi-species Mitochondrial Capture Kit | Precise Capture & Pan-taxa Coverage for Species Identification

In application scenarios such as species identification, evolutionary research and ecological monitoring, the mitochondrial genome is known as the "super barcode" due to its inherent advanta...



30

01, 2026

48-Hour Rapid Response! iGeneTech Nipah Virus Detection Solution Empowers Precision Epidemic Prevention & Control

Solution Highlights✅ 99.5%+ Whole Genome Coverage with 28,179 High-Specificity Probes✅ No Cultivation/Host Removal Required, Broad Sample Compatibility (Wastewater/Human-Derived/Environmental Sample...



28

01, 2026

Professor Guan Minxin's Team Wins the Second Prize of the Chinese Medical Science and Technology Award

On January 14, 2026, the official website of the Chinese Medical Association announced the evaluation results of the 2025 Chinese Medical Science and Technology Award. The scientific research achievem...



21

01, 2026

iGeneTech Pathogen Identification Solution for Febrile Hemorrhagic Syndrome

HDT Is Stepping into the Spotlight: Standing at the End of 2025, Reinterpreting the Harshness and Fairness of the NGS Upper Stream — An Interview with Dr. Cai Wanshi, CEO of iGeneTechLooking back at ...



15

01, 2026

iGeneTech CEO: Looking Back at 2025, Reinterpreting LDT

HDT Is Stepping into the Spotlight: Standing at the End of 2025, Reinterpreting the Harshness and Fairness of the NGS Upper Stream — An Interview with Dr. Cai Wanshi, CEO of iGeneTechLooking back at ...



12

01, 2026

Powered by 110,000 Probes: Simultaneous Detection of Multiple Pathogens for Gastrointestinal (GI) Syndrome

Recently, the National Administration of Disease Prevention and Control (NADC) organized a specialized meeting on infectious disease prevention and control, clearly pointing out that winter and spring...



08

01, 2026

Anchored in clinical needs, we embark on the next decade

iGeneTech: Forging Ahead into the Second Decade with Clinical Needs at the CoreFounded in 2014, iGeneTech officially stepped onto the threshold of its second decade in 2025.This year, our understandin...



31

12, 2025

Complete Analysis of iGeneTech Methylation Technology Platform: A One-Stop Solution from Library Construction to Target Capture

In the fields of epigenetics research and early cancer screening, DNA methylation testing has become one of the core technologies. As a leader in domestic gene capture technology, iGeneTech has launch...

